Bioventus Inc. (BVS) fair value analysis

Nasdaq · Updated 2026-09-07

Bioventus Inc. is a healthcare company that develops and commercializes orthopedic solutions, including products for joint preservation and regenerative medicine. The company operates primarily in the United States and internationally through its portfolio of surgical and non-surgical treatments for musculoskeletal conditions.

Forward Fair Value verdict

Fairly valued

Based on TickrTrends' weekly Forward Fair Value model, BVS is trading at within about 10% of estimated fair value.

BVS currently ranks #85 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Fairly valued for 3 consecutive weekly runs.

Last price: $13.47
Sector: Healthcare
12-month range: $6.56–$13.47

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: D
Leverage: Moderate
RSI zone: Neutral
50/200-day trend: Uptrend
52-week position: The top quarter of its range

What our data shows for BVS

Our model validated 13 trailing price-to-earnings windows for BVS, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $6.56–$13.47.
The 14-day relative strength index sits at a neutral 41.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for BVS
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent BVS news

TickrTrends' derived news-sentiment signal for BVS is currently leaning positive, computed from recent coverage.

Bioventus Inc (BVS) Stock Up 5.1% but GF Value Says Overvalued -- GF Score: 58/100 (gurufocus.com, 2026-09-03)
TickrTrends take: Bioventus stock gained 5 percent in recent trading, yet GuruFocus valuation metrics suggest the market price exceeds intrinsic value levels. This creates a divergence between TickrTrends' fairly valued assessment and GuruFocus's overvaluation signal, leaving valuation-conscious investors to reconcile two different analytical frameworks. A healthcare investor monitoring BVS should track whether the GF Score of 58 out of 100 and the overvaluation signal persist or whether operational improvements might justify current pricing.
Bioventus (BVS) Q2 2026 Earnings Call Transcript (finance.yahoo.com, 2026-08-13)
TickrTrends take: Bioventus reported Q2 2026 earnings results, providing updated financial performance metrics that inform its current valuation assessment. Given TickrTrends' determination that BVS is fairly valued, investors focused on valuation should monitor whether the company's Q2 results demonstrate earnings growth or margin performance sufficient to justify its current trading multiple within the competitive Healthcare sector. Key metrics from this earnings call, including revenue trends and profitability measures, will be relevant to assessing whether fair value positioning remains appropriate or warrants reconsideration.
Bioventus Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:BVS) 2026-08-05 (seekingalpha.com, 2026-08-05)
TickrTrends take: Bioventus released its second quarter 2026 earnings presentation, providing updated financial performance data relevant to assessing the company's valuation against its Healthcare sector peers. TickrTrends currently characterizes BVS as fairly valued, suggesting the market price reflects the company's fundamentals without significant upside or downside margin of safety. Investors focused on valuation metrics should examine whether the company's 2026 operational results support this assessment or signal potential changes to its current valuation standing.

What people are saying

Follow the BVS conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — TickrTrends' derived indicators for BVS showed a change in momentum this week, with the momentum indicator downgrading from a B rating to none. The stock remains in the Healthcare sector and maintains a current valuation verdict of fairly valued.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is BVS stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), BVS is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.

What is BVS's TickrTrends verdict?

BVS's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.

How does BVS compare to other Healthcare stocks?

BVS ranks #85 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is BVS overbought or oversold?

BVS's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

BVS vs ABBV · BVS vs BIIB · BVS vs BIO · BVS vs JAZZ · BVS vs MCK